Skip to content

NEI Research News

Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.

Source
268 items
little boy with eye patch simultaneously writing.

Extended daily eye patching effective at treating stubborn amblyopia in children

The standard treatment for amblyopia, a condition of poor vision in an otherwise healthy eye, is patching: covering a child’s better-seeing eye with a patch for two hours a day to improve vision in the weaker eye.
2 young boys hold balls and smile at the camera

NIH study provides clarity on supplements for protection against blinding eye disease

Adding omega-3 fatty acids did not improve a combination of nutritional supplements commonly recommended for treating age-related macular degeneration (AMD), a major cause of vision loss among older Americans.
NIH National Eye Institute logo

NEI-Funded Device for People with RP Gets FDA Approval

On February 14, 2013, the U.S. Food and Drug Administration approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP).
Two boys smile at camera. Dark spot in center of image represents vision loss from AMD.

NIH study suggests immune system could play a central role in AMD

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.
National Eye Institute logo.

Avastin and Lucentis are equivalent in treating age-related macular degeneration

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD).
National Eye Institute logo.

Funded by National Eye Institute, Makers of Bionic Eye Receive Eight Millionth Patent

The Argus II retinal prosthesis, developed by Second Sight, Inc., with funding from the National Eye Institute (NEI), was recognized September 8, 2011, in honor of being the 8 millionth patent issued by the United States Patent and Trademark Office.
National Eye Institute logo.

National Institutes of Health releases data from largest pediatric eye study

Study estimates prevalence of vision disorders among preschool children in three ethnic groups, identifies risk factors
NIH National Eye Institute logo

NIH study shows two treatments for uveitis equally effective

Treating patients with severe cases of uveitis, the fifth leading cause of vision loss in the United States, either locally with eye implants or systemically with anti-inflammatory medications improved vision similarly over two years.
National Eye Institute logo.

NIH study finds Avastin and Lucentis are equally effective in treating age-related macular degeneration

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).
National Eye Institute logo.

NIH adds first images to major research database

More than 72,000 clinical photographs illustrate age-related eye disease progression

Want more news from NEI?

Subscribe to our news feed to stay up to date on vision and eye health research!

Success! Link copied to clipboard.

Copy to clipboard failed.

You can also browse older stories in our news archive

NEI Press Office

We can connect media professionals with the latest vision research info. Get in touch!


Phone: 301-496-5248